Wet-electrospun biodegradable scaffold and uses therefor

US9901659B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9901659-B2
Application numberUS-201113698757-A
CountryUS
Kind codeB2
Filing dateMay 27, 2011
Priority dateMay 27, 2010
Publication dateFeb 27, 2018
Grant dateFeb 27, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A cell growth matrix is provided that comprises a biodegradable elastomeric polymer electrodeposited concurrently with a sprayed or electrosprayed liquid that is a physiological solution or which comprises a mammalian blood product such as serum, plasma or platelet rich plasma. The matrix is useful as a cell-growth matrix and for repair of a tissue in a mammal, for instance by implantation in a mammal at a site in need of repair, such as in an abdominal wall.

First claim

Opening claim text (preview).

We claim: 1. A method of repairing damaged or defective abdominal wall tissue in a mammal, comprising: implanting in the abdominal wall of the mammal at the site of the damaged or defective tissue a cell-free matrix comprising: a biodegradable elastomeric polymer, comprising one or both of a poly(ester carbonate)urethane urea (PECUU) and a poly(carbonate)urethane urea (PCUU), electrodeposited concurrently with a sprayed or electrosprayed liquid that comprises a cell-free mammalian blood product that is allogeneic to the mammal, thereby resulting in infiltration and growth of skeletal muscle cells, and mature vascular formation in the matrix, and thereby repairing the damaged or defective abdominal wall tissue. 2. The method of claim 1 , in which the liquid comprises one or more of serum, plasma and platelet rich plasma. 3. The method of claim 1 , in which the mammal is a human. 4. The method of claim 1 , in which the sprayed or electrosprayed liquid comprises from 1% to 100% v/v of a mammalian blood product. 5. The method of claim 1 , in which the sprayed or electrosprayed liquid comprises 100% serum, plasma or platelet rich plasma. 6. The method of claim 1 , in which the sprayed or electrosprayed liquid comprises from 10% to 30% v/v serum, plasma or platelet rich plasma. 7. The method of claim 1 , in which the sprayed or electrosprayed liquid comprises 20% v/v serum, plasma or platelet rich plasma. 8. The method of claim 1 , in which the sprayed or electrosprayed liquid comprises fetal bovine serum and horse serum and optionally chick embryo extract. 9. The method of claim 1 , in which the sprayed or electrosprayed liquid comprises a platelet rich plasma. 10. The method of claim 1 , in which the matrix is electrospun. 11. The method of claim 1 , in which the implant is implanted in the abdominal wall of the mammal, thereby repairing a defect in the abdominal wall of the mammal. 12. The method of claim 1 , wherein the polymer further comprises collagen. 13. The method of claim 1 , wherein the polymer further comprises elastin. 14. The method of claim 1 , wherein the polymer further comprises collagen and elastin. 15. The method of claim 1 , wherein the polymer comprises PCUU. 16. The method of claim 1 , wherein the polymer comprises PECUU. 17. The method of claim 1 , wherein the cell-free matrix further comprises at least one active agent selected from the group consisting of anti-inflammatories, immunosuppressants, antiangiogenic compositions, antiproliferative compositions, antibodies, compositions that act on immunophilins, taxanes, nitric oxide donors, antibiotics, growth factors, and combinations thereof. 18. A method of making a cell-free implantable matrix for muscle repair, comprising electrodepositing one or both of a poly(ester carbonate)urethane urea (PECUU) and a poly(carbonate)urethane urea (PCUU) and concurrently electrospraying a liquid comprising a cell-free mammalian blood product onto the electrodeposited polymer. 19. The method of claim 18 , wherein the PCUU comprises poly(1,6-hexamethylene carbonate). 20. The method of claim 19 , wherein a molar ratio of PCL:PHC is 75:25, 50:50, or 25:75. 21. The method of claim 18 , wherein the PECUU comprises polycaprolactone (PCL) and poly(1,6-hexamethylene carbonate) (PHC).

Assignees

Inventors

Classifications

  • Blood, e.g. platelet-rich plasma · CPC title

  • obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds · CPC title

  • Synthetic polymers · CPC title

  • A61L27/58Primary

    Materials at least partially resorbable by the body · CPC title

  • General culture methods using substrates (for specific animal cell type C12N5/06) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9901659B2 cover?
A cell growth matrix is provided that comprises a biodegradable elastomeric polymer electrodeposited concurrently with a sprayed or electrosprayed liquid that is a physiological solution or which comprises a mammalian blood product such as serum, plasma or platelet rich plasma. The matrix is useful as a cell-growth matrix and for repair of a tissue in a mammal, for instance by implantation in a…
Who is the assignee on this patent?
Hong Yi, Amoroso Nicholas J, Fujimoto Kazuro Lee, and 3 more
What technology area does this patent fall under?
Primary CPC classification A61L27/3616. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).